ReviewEuropean journal of immunology2020
All the small things: How virus-like particles and liposomes modulate allergic immune responses.
Review in European journal of immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Liposomal Delivery Systems for Allergen-Specific Immunotherapy: From Molecular Design to Clinical Application.Membranes · 2026Review
- Nanomaterials in Targeted Immunotherapy for Chronic Spontaneous Urticaria: Focusing on Immune Cell Modulation and Precision Treatment.International journal of nanomedicine · 2026Review
- Macropinocytosis Is the Principal Uptake Mechanism of Antigen-Presenting Cells for Allergen-Specific Virus-like Nanoparticles.Vaccines · 2024Article
- Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.International journal of molecular sciences · 2024Review
- Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.International journal of nanomedicine · 2024Review
- SARS-CoV-2 virus-like-particlesNanoscale advances · 2023Article
- Mechanistic insights into silica nanoparticle-allergen interactions on antigen presenting cell function in the context of allergic reactions.Nanoscale · 2023Article
- Bottom-up assembly of viral replication cycles.Nature communications · 2022Review
- Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein.Nature communications · 2022Article
- New Therapeutic Approaches for Allergy: A Review of Cell Therapy and Bio- or Nano-Material-Based Strategies.Pharmaceutics · 2021Review
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- Review
- Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Recent years have seen a dramatic increase in the range of applications of virus-like nanoparticle (VNP)- and liposome-based antigen delivery systems for the treatment of allergies. These platforms rely on a growing number of inert virus-backbones or distinct lipid formulations and intend to engage the host's innate and/or adaptive immune system by virtue of their co-delivered immunogens. Due to their particulate nature, VNP and liposomal preparations are also capable of breaking tolerance against endogenous cytokines, Igs, and their receptors, allowing for the facile induction of anti-cytokine, anti-IgE, or anti-FcεR antibodies in the host. We here discuss the "pros and cons" of inducing such neutralizing autoantibodies. Moreover, we cover another major theme of the last years, i.e., the engineering of non-anaphylactogenic particles and the elucidation of the parameters relevant for the specific trafficking and processing of such particles in vivo. Finally, we put the various technical advances in VNP- and liposome-research into (pre-)clinical context by referring and critically discussing the relevant studies performed to treat allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.